Phase II evaluation of echinomycin (NSC-526417) in patients with central nervous system malignancies: A southwest oncology group study
Abstract
The objective of this trial was to determine the efficacy of echinomycin (1.2 mg/m2) administered on a weekly times four schedule in the treatment of patients with recurrent or progressive central nervous malignancies despite adequate radiotherapy. Thirty-five patients were registered on study. The majority of patients (20) had glioblastoma multiforme. Ten had anaplastic astrocytoma. Eight patients had received prior nitrosoureas. SWOG performance status was 1 in 11 patients and 2 in 22. The median age was 51 years (25-75 years). One patient had a partial remission (3%:95% confidence interval: 1%-16%). Twenty two patients had progressive disease. The median survival was 5.9 months. Toxicity was primarily gastrointestinal with nausea and vomiting in 13 patients and nausea only in 11 patients. Hepatotoxicity occurred in 10 patients. Echinomycin given at this dose and schedule is not effective in treating patients with recurrent or progressive glioblastoma multiforme or anaplastic astrocytomas.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical development of echinomycin was discontinued because it was not effective for patients with solid tumors refractory to all available treatments.
“However, clinical development was discontinued because echinomycin was not found to be effective for patients with solid tumors that were refractory to all available treatments.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [17]
CrEL-echinomycin caused severe nausea and vomiting, constituting its dose-limiting toxicity.
“CrEL-echinomycin also caused severe nausea and vomiting, constituting its dose-limiting toxicity11, 12, 15-21.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [17]
Clinical studies have provided considerable safety data for echinomycin.
“Clinical studies have provided considerable safety data for echinomycin10-12, 14-18, 41-45”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [17]
The citation lists haven’t been fetched yet
References 6 · Cited by 15
- Authors
- Taylor, S. A., Crowley, J., Townsend, J., Vogel, F. S., Eyre, H., Braun, J. J., & Goodwin, J. W.
- Affiliations
- University of Kansas Medical Center (US)
- SWOG Cancer Research Network (US)
- University of Utah (US)
- Duke Medical Center (US)
- University of Colorado Denver (US)
- ORCID
- Taylor, Sarah A.
- Venue
- Journal of Neuro-Oncology
- Published
- 1993-02
- Volume
- 15
- Issue
- 2
- Pages
- 181-184
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- OpenAlex
- W2318425335
- Cited by
- 15
- References
- 6
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 2
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neuro-Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u10ca013238-16)
- National Cancer Institute (CA 13238, CA 37429, CA-12644, U10CA012644, U10CA037429)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Brain Metastases and Treatment
- Keywords
- echinomycin, central nervous system malignancies, glioblastoma, anaplastic astrocytoma, recurrent brain tumors, weekly dosing, antineoplastic efficacy, hepatotoxicity, gastrointestinal toxicity, survival
- MeSH terms
- Adult, Aged, Brain Neoplasms, Drug Administration Schedule, Echinomycin, Female, Glioma, Humans, Male, Middle Aged, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
